Summary
Global Markets Direct’s, ‘Hidradenitis Suppurativa - Pipeline Review, H2 2016’, provides an overview of the Hidradenitis Suppurativa pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
- The report reviews pipeline therapeutics for Hidradenitis Suppurativa by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hidradenitis Suppurativa therapeutics and enlists all their major and minor projects
- The report assesses Hidradenitis Suppurativa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Cellceutix Corporation
Celtaxsys, Inc.
Delenex Therapeutics AG
Johnson & Johnson
Novartis AG
Sandoz International GmbH
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hidradenitis Suppurativa Overview 6
Therapeutics Development 7
Pipeline Products for Hidradenitis Suppurativa - Overview 7
Hidradenitis Suppurativa - Therapeutics under Development by Companies 8
Hidradenitis Suppurativa - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Hidradenitis Suppurativa - Products under Development by Companies 12
Hidradenitis Suppurativa - Companies Involved in Therapeutics Development 13
Cellceutix Corporation 13
Celtaxsys, Inc. 14
Delenex Therapeutics AG 15
Johnson & Johnson 16
Novartis AG 17
Sandoz International GmbH 18
Hidradenitis Suppurativa - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
acebilustat - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
adalimumab biosimilar - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
adalimumab biosimilar - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
brilacidin tetrahydrochloride - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CJM-112 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
DLX-105 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
DLX-2751 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ustekinumab - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Xilonix - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Hidradenitis Suppurativa - Dormant Projects 59
Hidradenitis Suppurativa - Discontinued Products 60
Hidradenitis Suppurativa - Product Development Milestones 61
Featured News & Press Releases 61
Sep 11, 2014: Delenex Announces New Clinical Data 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63
List of Tables
Number of Products under Development for Hidradenitis Suppurativa, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Hidradenitis Suppurativa - Pipeline by Cellceutix Corporation, H2 2016 13
Hidradenitis Suppurativa - Pipeline by Celtaxsys, Inc., H2 2016 14
Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H2 2016 15
Hidradenitis Suppurativa - Pipeline by Johnson & Johnson, H2 2016 16
Hidradenitis Suppurativa - Pipeline by Novartis AG, H2 2016 17
Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Hidradenitis Suppurativa - Dormant Projects, H2 2016 59
Hidradenitis Suppurativa - Discontinued Products, H2 2016 60
List of Figures
Number of Products under Development for Hidradenitis Suppurativa, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26
